Novel target could treat both SARS-CoV-2 and other coronaviruses
Scientists shows targeting cholesterol or phosphatidylinositol phosphate (PIP) could be a promising strategy to combat multiple coronaviruses.
List view / Grid view
Scientists shows targeting cholesterol or phosphatidylinositol phosphate (PIP) could be a promising strategy to combat multiple coronaviruses.
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
Elevated levels of a biomarker related to blood vessel damage have been found in all children with SARS-CoV-2 infection.
A long-term study of macaques given mitochondrial replacement therapy (MRT) found that both treated individuals and their offspring were healthy and developed normally.
Researchers have shown how increased YTHDF3 expression correlates with brain cancer metastases, making it a target for the condition.
Mice treated with a small molecule inhibitor of cadherin 11 (CDH11) had reduced pancreatic cancer growth and increased survival time.
Investigators found that red propolis can kill schistosomes at all stages of development and therefore suggest it could be highly effective for treating schistosomiasis.
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
Engineered deubiquitinases combines a synthetic nanobody that recognises a protein that can rescue proteins tagged for destruction.
Next-generation sequencing will be employed to study 1,500 plasma proteins in participants, according to UK Biobank.
Study suggests reducing the expression of the methyl-CpG-binding domain 2 (MBD2) protein on macrophages could be a viable therapeutic strategy for lung fibrosis.
Scientists suggest that research using XPSCs, an intermediate form of embryonic stem cell, could help accelerate the development of stem cell-derived tissues and organs for transplantation.
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
Researchers show that neutralising antibodies targeting the SARS-CoV-2 Spike protein have four distinct structures.
Researchers have developed a novel insulin molecule that responds to glucose levels in the blood sugar of rats, which they say could help patients with type 1 diabetes.